FDA Continues Approval of Immunotherapy Drugs Valuable In Mesothelioma Care – MesotheliomaHelp.org (blog)
|
FDA Continues Approval of Immunotherapy Drugs Valuable In Mesothelioma Care
MesotheliomaHelp.org (blog) The U.S. Food and Drug Administration announced last month that it has granted Breakthrough Therapy Designation for the drug Imfinzi (durvalumab) in the treatment of non-small cell lung cancer. This approval brings one more immunotherapy option to lung … |
